- Earlier this week, InnovAge Holding Corp. was removed from several Russell value indices, including the Russell 3000 Value and Russell 2000 Value benchmarks, following the annual reconstitution process.
- Because many passive funds track these indices, InnovAge’s exclusion can alter the mix of institutional holders and reshape how the market views its profile within small-cap healthcare.
- Next, we’ll examine how InnovAge’s removal from multiple Russell value indices may influence the existing investment narrative around growth, margins, and risk.
We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
InnovAge Holding Investment Narrative Recap
To own InnovAge, you need to believe its PACE model can eventually translate rising revenue into sustainable profitability despite current losses and cost pressures. The Russell value index removals may affect trading liquidity and some institutional ownership, but they do not appear to change the near term focus on cost discipline and margin recovery, or the key risk around regulatory and reimbursement exposure.
The most directly relevant recent development is the appointment of Jennifer Browne as President and COO in May 2026, given her background in value based care and multi state operations. As InnovAge digests its index exits, execution under this refreshed leadership bench could be important for addressing cost growth, stabilizing new center performance, and supporting any future re rating of the shares.
Yet while index changes can look technical, investors should still pay close attention to InnovAge’s exposure to shifting Medicare and Medicaid funding...
Read the full narrative on InnovAge Holding (it's free!)
InnovAge Holding's narrative projects $1.2 billion revenue and $165.3 million earnings by 2029. This requires 6.8% yearly revenue growth and about a $176.9 million earnings increase from -$11.6 million today.
Uncover how InnovAge Holding's forecasts yield a $7.00 fair value, a 35% downside to its current price.
Exploring Other Perspectives
Two Simply Wall St Community fair value estimates for InnovAge currently span from US$7.00 to about US$27.54 per share, underscoring how far apart private investors can be. When you weigh those views against the ongoing risk that Medicare and Medicaid policy shifts could affect long term revenue, it becomes even more important to review several independent perspectives before forming a view on InnovAge’s future performance.
Explore 2 other fair value estimates on InnovAge Holding - why the stock might be worth 35% less than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your InnovAge Holding research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free InnovAge Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate InnovAge Holding's overall financial health at a glance.
Ready For A Different Approach?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
- Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com